Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quoin PharmaceuticalsSTU:2EB0 19 3-Year EBITDA Growth Rate is 78.00% as of Mar. 2026, which is 47% above its 10-year median of 53.20. GuruFocus rates STU:2EB0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Quoin Pharmaceuticals ranks better than 96.02% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 78.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 65.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Quoin Pharmaceuticals was 80.80% per year. The lowest was -22.80% per year. And the median was 53.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Quoin Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
STU:2EB0 vs VTGN, SYBX, APRE: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Quoin Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quoin Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Quoin Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 78.00% mean?
Quoin Pharmaceuticals (STU:2EB0) has a 3-Year EBITDA Growth Rate of 78.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Quoin Pharmaceuticals and its competitors. This is 47% above median its historical median of 53.20. According to the industry distribution chart, Quoin Pharmaceuticals ranks #45 out of 1131 companies in the Biotechnology industry, placing it in the top 4%.
Is Quoin Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Quoin Pharmaceuticals' current 3-Year EBITDA Growth Rate of 78.00% is 47% above median its 10-year median of 53.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Quoin Pharmaceuticals' value of 78.00% is 423.5% above this industry median. Based on the distribution chart, Quoin Pharmaceuticals ranks #45 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Quoin Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Quoin Pharmaceuticals' 3-Year EBITDA Growth Rate compare to VTGN and SYBX?
According to the Biotechnology industry distribution chart, Quoin Pharmaceuticals ranks #45 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Quoin Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Quoin Pharmaceuticals' value of 78.00% is 423.5% above this benchmark. While the company's 10-year median is 53.20 vs. the industry median of 14.90, Quoin Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quoin Pharmaceuticals's current 3-Year EBITDA Growth Rate of 78.00% is 423.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Quoin Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quoin Pharmaceuticals's current 3-Year EBITDA Growth Rate is 78.00%, which is 47% above median its own 10-year median of 53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quoin Pharmaceuticals stock overvalued right now?
Quoin Pharmaceuticals (STU:2EB0) has a current 3-Year EBITDA Growth Rate of 78.00%. The current 3-Year EBITDA Growth Rate is 78.00%, which is 47% above median its 10-year median of 53.20 and 423.5% above the Biotechnology industry median of 14.90. Quoin Pharmaceuticals' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Quoin Pharmaceuticals (STU:2EB0), the current 3-Year EBITDA Growth Rate is 78.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
19GF Score
Get the complete analysis for STU:2EB0
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2EB0 has been successfully added to your 
